Background-The age standardised mortality rate per 100 000 population for all causes of liver tumours (International Classification of Disease 9 (ICD-9) 155) has almost doubled in England and Wales during the period 1979-1996. We further analysed the mortality statistics to determine which anatomical subcategories were involved. Methods-Mortality statistics for liver tumours of ICD-9 155, 156, and subcategories, and for tumours of the pancreas (ICD-9 157), in England and Wales were investigated from the OYce for National Statistics, London, from 1968 to 1996 inclusive. Data for 1997 and 1998 were also available on intrahepatic cholangiocarcinomas. Results-There has been a marked rise in age standardised mortality rates for intrahepatic cholangiocarcinoma. Since 1993, it represents the commonest recorded cause of liver tumour related death in England and Wales. This is evident in age groups older than 45 years. In contrast, mortality trends from other primary liver tumours, including hepatocellular carcinoma, were unremarkable. Conclusions-The observed increase in mortality from intrahepatic cholangiocarcinoma may represent better case ascertainment and diagnosis due to improved diagnostic imaging, use of image guided biopsies, or increased use of ERCP. However, the trend started before ERCP was introduced nationally, mortality rates have continued to increase steadily thereafter, and there is no clear evidence that diagnostic transfers easily explains the findings. Alternatively, these observations may represent a true increase in intrahepatic bile duct tumours. Epidemiological studies are required to determine whether there is any geographical clustering of cases around the UK. (Gut 2001;48:816-820) 
Studies from France, Italy, and the USA suggest that the incidence of hepatocellular carcinoma (HCC) is increasing, 1 2 and this may be related to chronic hepatitis C virus (HCV) infection. [1] [2] [3] [4] Age standardised mortality rates (ASMR) for all causes of malignant liver tumours (International Classification of Disease 9 (ICD-9) 155) have increased from 1979 to 1994 in the UK, 5 but unlike in Southern Europe, the ASMR for HCC has been reported to be relatively static over this time period while the ASMR for intrahepatic cholangiocarcinoma may have been increasing. 5 We investigated ASMR and age specific mortality rates (ASpMR) for all liver tumours in England and Wales, starting in 1968, when comparable mortality records began, to determine when the rise in ASMR for intrahepatic cholangiocarcinoma first started and which age groups have primarily been aVected.
Methods
Mortality data for 1968-1996 were obtained for the English and Welsh populations from the OYce for National Statistics (ONS) in London. Information was requested on: x ICD-9 155 (all malignant liver tumours) x ICD-9 155.0 (primary liver tumours, mainly HCC) x ICD-9 155.1 (intrahepatic cholangiocarcinoma) x ICD-9 155.2 (histologically unspecified liver tumours) x ICD-9 156 (all extrahepatic biliary system tumours) x ICD-9 156.0 (gall bladder tumours) x ICD-9 156.1 (tumours of the extrahepatic bile ducts) x ICD-9 157 (pancreatic tumours).
The ICD-9 155.0 code contains information on all primary tumours of the hepatic parenchyma but is overwhelmingly composed of data on HCC. Mortality data, supplied in five year age bands, were considered to be an indicator of incidence because prognosis from liver cancer is poor. Additional mortality data for 1997-1998 were requested, once they had become available, for intrahepatic cholangiocarcinoma, the tumour of primary interest, as initial analysis indicated that the observed trends for this tumour warranted further up to date inspection.
NUMBER OF DEATHS
The total number of deaths attributed to each ICD category of cancers was analysed by year and sex. No deaths before 1968 are included because coding changes between ICD-7 (1958 ICD-7 ( -1967 and ICD-8 (1968 ICD-8 ( -1978 make it impossible to accurately trace deaths attributed to a particular category earlier than this. Coding changes between ICD-8 and ICD-9 for the tumours under study seemed to be minor, although it is recognised that any change in coding can have an impact on mortality statistics. 6 In our analysis, we mapped the change in code for "unspecified primary or secondary tumours of the liver" across ICD revisions from 197.8 to 155.2.
Two other notable changes to the collection and coding of deaths in England and Wales occurred in 1993 which may aVect interpretation of trends in mortality. These include the move back by the OYce of Population Censuses and Surveys (OPCS) to the internationally accepted interpretation of World Health Organization (WHO) rule 3, regarding the selection of the underlying cause of death, which was in operation before 1984. 7 In addition, until 1992 it was standard procedure for the OPCS to apply to the person certifying the death for further information regarding the underlying cause of death when the conditions mentioned on the death certificate were vague. The use of such "medical enquiries" to help assign a more definite code to the underlying cause of death was discontinued in 1993. 7 
AGE STANDARDISED MORTALITY RATES
ASMR per 100 000 population were calculated using direct standardisation with the European standard population as a reference population. 8 
AGE SPECIFIC MORTALITY RATES
Initially, ASpMR per 100 000 of the population were analysed by five year age bands but given that tumours are much less common in the younger age groups and that treatment and management may diVer between middle and very old age, these were aggregated into more clinically relevant age specific groups. The following age bands were therefore chosen: 20-44, 45-64, 65-74, and 75+.
Results

ALL LIVER TUMOURS
ASMR per 100 000 population for the combined causes of malignant liver tumours increased steadily in the period 1968-1996 from 1.29 to 1.93 in females and from 2.56 to 3.70 in males ( fig 1A, B) . Total numbers of deaths increased from 967 (396 females; 571 males) in 1968 to 1822 (770 females; 1052 males) in 1996 (table 1) .
Primary liver tumours including hepatocellular carcinomas
Data on primary liver tumours revealed fluctuations in ASMR about a stable mean between 1968 and 1978 for both sexes. However, in 1979 there was a noticeable increase in ASMR for both males and females until 1992 ( fig 1A, B) . In 1993 there was a sharp decline in ASMR to levels more in common with those before 1979.
Intrahepatic cholangiocarcinoma ASMR per 100 000 population for intrahepatic cholangiocarcinoma increased markedly for both sexes over the period (fig 1A,  B) . There was a 15-fold increase in ASpMR per 100 000 population in ages 45 and above (fig 2A, B) . The total number of deaths increased from 38 (17 (table 1) . Additional data for 1997-1998 showed a further marked increase in mortality rates from the 1996 statistics. ASMR increased from 0.92 and 1.22 in 1996 to 1.12 and 1.37 in 1998 for females and males, respectively, bringing the total number of deaths in that year to 864.
Unspecified tumours of the liver ASMR for liver tumours in this ICD category showed a small decrease overall, although there was a marked fall in ASMR from 1978 to 1993 in both sexes ( fig 1A, B) .
TUMOURS OF THE GALL BLADDER AND EXTRAHEPATIC BILIARY TREE
There was a steady decrease in ASMR between 1968 and 1996 ( fig 1A, B) . Between 1968 and 1978, the total number of deaths for men and women was relatively stable at approximately 700 per year for women and approximately 400 per year for men. Subsequently, the total number of deaths fell from 1043 in 1979 to 585 in 1996 (table 1) .
Tumours of the gall bladder
Between 1968 and 1996, both ASMR and total number of deaths attributed to malignant neoplasm of the gall bladder decreased steadily. ASMR fell from 1.21 and 0.84 in 1968 to 0.55 and 0.30 in 1996 for females and males, respectively.
Tumours of the extrahepatic bile ducts
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Discussion
In England and Wales there has been a steady rise in mortality coded to intrahepatic cholangiocarcinoma. Although ASMR for extrahepatic cholangiocarcinoma have decreased, the increase in intrahepatic tumours outweighs this with a rise in ASMR and in absolute number of deaths for both these two ICD-9 categories combined. Cholangiocarcinoma, arising from the intrahepatic biliary tree, is much less common than HCC on a worldwide basis, but since 1993 this tumour is the commonest recorded cause of malignant liver tumour related death in England and Wales. In South East Asia and China, development of cholangiocarcinoma is mainly associated with liver flukes. 9 In the West the aetiology is largely unknown although the obsolete radiological contrast agent thorotrast has been implicated in causing cholangiocarcinoma. 10 Smoking and alcohol have also been implicated but the evidence is weak. 11 12 Primary sclerosing cholangitis is the commonest predisposing factor in the UK but it is associated with only a minority of cases. 9 The steadily increasing ASMR for intrahepatic cholangiocarcinoma may represent an artefactual trend, introduced into the mortality figures by improvement in diagnosis (case ascertainment) resulting from better imaging techniques, by changes in coding practices, or from misclassification of ICD coding (diagnostic transfer). It is also possible that this trend represents a real increase in mortality from this tumour.
Better ascertainment from improved diagnostic imaging, use of image guided biopsies, and from the national availability of techniques such as endoscopic retrograde cholangiopancreatography (ERCP) could account for these observations. ERCP was first available in the UK in the late 1970s after the rise in ASMR started, and became available in most UK hospitals in the mid 1980s. 13 14 The increased mortality rates have continued after the initial endoscopic learning curve and the general availability of the technique should have led to an expected plateau in these values. It is therefore unlikely that our observations on intrahepatic cholangiocarcinoma are solely caused by an improvement in diagnosis from ERCP. Furthermore, it is the distally located extrahepatic bile duct tumours, total numbers of deaths from which have actually decreased, that are more easily visualised with ERCP, rather than the intrahepatic tumours which often involve much smaller bile ducts. The definitive diagnosis of intrahepatic bile duct tumours is histological, and in a large proportion of cases this is made from tissue obtained at surgery or at post mortem. 15 However, this is dependent on the experience of the local pathologist and therefore there may be interobserver diVerences in interpretation. This factor in itself would not account for the year-on-year rise in intrahepatic cholangiocarcinoma that we have reported.
There have been a few changes to the collection and coding of mortality data from 1968 to 1998 which could potentially render our findings artefactual. However, no discernible "steps" in mortality trends for intrahepatic cholangiocarcinoma have been introduced by changes in coding practices. This is in stark contrast with the mortality trends for primary liver tumours (mainly HCC) and for unspecified liver tumours, which provide clear illustrations of the impact of coding changes. In 1979 when ICD-9 was first introduced, subtle changes in the number and type of diseases which fed into both these categories of tumours led to an increase in primary liver tumours and a simultaneous decline in unspecified liver tumours. In 1993, both the rule 3 coding change and the death certificate changes introduced further artefact, with the latter having the dominant eVect on these tumour types. Prior to 1993, it was routine practice for OPCS to obtain follow up information from the certifying doctor about the cause of death, approximately six weeks after the initial death certification. In many instances, information that became available with post mortem confirmed or changed the cause of death and this was rectified with this process. With the absence of follow up medical enquiries on death certificates from 1993, there was an increase in the number of deaths assigned to categories of less specific causes. 7 The sudden change in mortality statistics between 1979 and 1993 for primary and unspecified liver tumours are thus artefactual and any examination of time trends for these tumours is limited to cautious comparisons of data from before 1979 and after 1993.
Diagnostic transfer from tumours of the gall bladder and extrahepatic biliary tree to intrahepatic cholangiocarcinomas is an alternative explanation for our findings but the increase in ASMR and absolute number of deaths from intrahepatic tumours outweighed the decrease in the other malignancies. Simple diagnostic transfer is therefore unlikely. Diagnostic transfer may also occur between intrahepatic cholangiocarcinoma and undiVerentiated metastatic adenocarcinoma in the liver but it is probable that histologically ill defined tumours tend to be reported in the unspecified category than reported specifically as intrahepatic cholangiocarcinoma. 16 Diagnostic transfer from pancreas to intrahepatic cholangiocarcinoma could account for the small decrease in ASMR for pancreatic tumours and the marked increase in ASMR for intrahepatic bile duct tumours but this is unlikely because it is unusual to confuse the two diagnoses from an anatomical standpoint.
Another explanation for the steady rise in ASMR for intrahepatic cholangiocarcinoma between 1968 and 1998 is a true increase in incidence of this tumour. The reason intrahepatic cholangiocarcinomas have increased in place of tumours of the rest of the biliary tract may be because of the larger surface area of the intrahepatic biliary tree 17 compared with that of the gall bladder and extrahepatic biliary tree, allowing greater exposure to potential carcinogens, which may have been more prevalent over the past 30 years. Furthermore, intrahepatic bile ducts contain the majority of actively dividing cholangiocytes, which would make malignancies of this part of the biliary tree more likely. 18 If improved imaging and the availability of ERCP has led to better case ascertainment, intrahepatic tumours may be detected at an earlier stage, before invasion of the extrahepatic biliary tree has occurred. However, the absolute rise in both ASMR and total number of deaths from the combined ICD-9 categories for intra-and extrahepatic bile duct tumours is also further evidence that the observed trend may, in part, be real rather than apparent.
The oral contraceptive pill has also been implicated in the development of cholangiocarcinoma 19 20 although case control studies have failed to substantiate an increased risk. 21 The time period when oral contraceptives became widely available in England and Wales and the age groups involved with increased mortality from intrahepatic cholangiocarcinoma do not entirely match. 22 Furthermore, this trend in mortality statistics is also seen in men, making the "pill" an unlikely candidate as the sole cause of this phenomenon, although there are many chemicals which could potentially have entered the food chain which have oestrogenic properties.
We have shown a dramatic increase in ASMR and ASpMR for intrahepatic cholangiocarcinoma from 1968 to 1998 in England and Wales. Epidemiological studies are required to determine whether there is any geographical clustering of cases around the UK and whether any clusters can be related to occupational exposure. Further studies are needed to compare the observed trend in mortality statistics with that for other countries. Given that current treatment outcomes for cholangiocarcinoma are poor, such studies may lead to a better understanding of the aetiology of these tumours and institution of appropriate preventative measures.
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LETTERS TO THE EDITOR
Ulcerative colitis is more strongly linked to chromosome 12 than Crohn's disease EDITOR,-Lesage and colleagues reported failure to detect linkage to the IBD2 locus on chromosome 12 in a panel of 95 families with two or more relatives aVected by Crohn's disease, and oVered some possible explanations (Gut 2000;47:787-91). Linkage of inflammatory bowel disease (IBD) to this region was first detected in a panel of 160 families containing multiple cases of Crohn's disease, ulcerative colitis, or both. 1 Lesage et al justify the study of Crohn's disease families alone on the grounds that "genetic heterogeneity in susceptibility cannot be ruled out", and they imply that studying the Crohn's disease subgroup of IBD should thus maximise their chance of successful replication. We concur entirely that genetic heterogeneity is important, and we have recently reported strong evidence that it does indeed apply to chromosome 12.
2 However, our study of 367 multiply aVected families suggested a significantly stronger contribution of this locus to ulcerative colitis than Crohn's disease. 2 The diVerence between the linkage results for ulcerative colitis (LOD=3.91) and Crohn's disease (LOD=1.66) reached statistical significance in two separate tests for heterogeneity. In the light of these results, the validity of the exclusion map drawn by Lesage et al is undermined. The exclusion map was based on an assumed locus specific s of 2.0, but this value was derived from a panel containing Crohn's disease, ulcerative colitis, and mixed pairs. 1 Given the evidence for a substantially stronger contribution to ulcerative colitis than Crohn's disease, it is likely that the true s value for this locus with regard to Crohn's disease is much less than 2. Thus the contention that Lesage et al can exclude a contribution of IBD2 to Crohn's disease susceptibility is probably not valid. As pointed out in the accompanying editorial, simulation studies have demonstrated that lod scores can be expected to vary, particularly when the study population is relatively small. 3 Furthermore, the implication that a panel of 157 aVected relative pairs should provide suYcient power to detect linkage if this locus is contributing to disease susceptibility is at marked variance with the power calculations derived by Suarez et al, Mandal et al, and others. 4 5 In many respects, the surprising feature is that IBD2 has been replicated in as many as five independent panels. 3 The datasets that have failed to detect linkage at this locus have all contained predominantly or exclusively Crohn's disease pairs. [6] [7] [8] Although IBD2 probably does contribute to Crohn's disease susceptibility, the eVect is likely to be weak and thus would require very large panels of multiply aVected families to have a realistic expectation of replicating (or excluding) the linkage result.
It is our view that attempts at fine mapping IBD2 probably have the greatest chance of success if they concentrate on panels of families and individuals with ulcerative colitis, which appears to be significantly more strongly linked to this locus than Crohn's disease. 1 In a recently published study in the journal, we failed to demonstrate a positive linkage on chromosome 12 using an independent panel of 95 CD multiplex families (Gut 2000;47:787-91). This result was diVerent to the previous report and we proposed several explanations for the observed discrepancy.
The first explanation may be lack of statistical power in our replication study. We investigated a similar number of aVected relative pairs (n=157, all CD pairs) compared with the first linkage analysis (n=186, 81 CD pairs, 64 UC pairs, and 41 mixed pairs). Because linkage tests may exhibit large fluctuations when applied to family sets of similar size for complex genetic disorders, 2 we tested if a gene with a s risk of 2 was compatible with our observation and we were able to reject this hypothesis. We thus concluded that genetic heterogeneity may occur in Caucasian family panels for IBD susceptibility.
Parkes et al have recently demonstrated that this genetic heterogeneity may be related to phenotypic heterogeneity. 3 In their proposed susceptibility model, UC is more tightly linked to IBD2 than CD. This study confirms our conclusion that there is genetic heterogeneity in familial IBD. As expected, this heterogeneity may be in part reduced by an accurate phenotypic classification. Thus from a methodological point of view, Parkes' report demonstrates that working on homogeneous phenotypic groups may be preferable than pooling several phenotypes for linkage studies. Considering CD and UC families as separate subgroups, Parkes et al suggested that the IBD2 locus has only a marginal role in CD susceptibility. This conclusion is in complete accordance with our demonstration that the relative risk attributable to IBD2 in CD multiplex families is low.
In practice, it is diYcult to know what is the weight of this IBD2 locus in both CD and UC. A line of evidence, including the above mentioned reports, 3 and a large collaborative work performed on more that 600 multiplex IBD families 4 clearly suggests that the role of the IBD2 locus is weak in CD families. In contrast, its role in UC is diYcult to estimate to date. In their recent work, Parkes et al pooled previously investigated families from UK and US panels. 1 5 Because these families were a priori known to be positively linked to IBD2, this study provides a biased estimate of the risk attributable to IBD2. Thus additional works using unselected family panels are required to answer this question.
Interestingly, the IBD1 locus 6 has been postulated to play a major role in CD and to be less important in UC families. Thus it would be postulated that IBD1 is a CD susceptibility locus and IBD2 is a UC gene. Some truth may reside in this assertion. However, a line of evidence including analysis of mixed families 7 suggests that CD and UC have common familial risk factors and does not allow a simple dichotomic classification of UC and CD genes. Many additional steps, including gene identification, are now required before we can understand the underlying genetic model for IBD which will certainly be confirmed as a complex genetic disorder. and as an extracellular fluid volume marker suggests that, at least in part, mannitol diVuses through the intercellular tight junctions. Thus it seems justified talking of permeability for mannitol. One of the reasons for its use in combination with cellobiose is the diVerent molecular sizes of the two probes: the smaller size of mannitol allows its passage through the small tight junctions of the villi while the larger cellobiose passes through the larger tight junctions of the crypts.
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Finally, we did find an increase in cellobiose excretion after fluorouracil (5-FU) that was in part prevented by oral glutamine. Although this diVerence did not reach statistical significance, overall the data indicate increased intestinal permeability after 5-FU, partially prevented by oral glutamine. In cystic fibrosis (CF), the degree of correlation between CFTR genotype and CF phenotype varies between clinical components but is highest for pancreatic involvement. 4 CFTR mutations can simplify be divided into "severe" and "mild" with respect to the degree to which mutations impair CFTR function. 5 Approximately 85% of CF patients suVer from pancreatic insuYciency (PI) while ∼15% are pancreatic suYcient (PS). Generally patients with PI carry two "severe" mutations whereas PS is associated with at least one "mild" mutation ( fig 1) . In CF, pancreatitis is seen rather frequently in PS patients but not in PI patients. Today, more than 850 CF mutations have been reported to the CF Consortium (http\www.genet. sickkids.on.ca/cftr). The deletion delta-F508, accounting for about 70% of mutant CF alleles worldwide and approximately 53% in Spain, studied by Malats et al, is responsible for severe functional loss of CFTR function. Three additional studies on the prevalence of an abnormal CFTR allele in AP have been published as full papers. 3 6 7 Pooling these four studies, one or two mutant CFTR alleles were detected in 9/217 (4.1%) patients with AP. But the detection rate varies between 0% and 8.5% depending on the sensitivity of the screening method to detect an abnormal CF allele in the corresponding population (53-94%). None of the studies revealed a positive association of the 5T allele with IP or AP. Compared with the general population, delta-F508 was significantly more frequent in British and US Caucasian, but not in Australian or Spanish AP patients.
Up to now no environmental or genetic cofactor was identified in patients with mutant CFTR alleles associated IP, suggesting that impairment of CFTR function alone may be enough to induce pancreatitis. 1 2 3 8 9 On the other hand it may be speculated that patients with an abnormal CFTR allele, who develop pancreatitis in conjunction with alcohol abuse, may be characterised by a higher residual CFTR function, which by itself is not capable of inducing pancreatitis.
Therefore, to delineate the genetic background of pancreatic disease in AP it seems to be more appropriate to investigate the prevalence of uncommon mild variants ("atypical mutations") in large cohorts of AP patients than to test for the more common ("severe, typical") mutations of the CFTR gene in small patient groups. It has to be considered that the test kits for CFTR mutations often used in routine screening are usually designed to detect the more severe CF mutations. This would result in missing a substantial number of patients with milder CFTR mutations, as suggested by preliminary data on more comprehensive genetic testing in patients with ICP. the role of this gene in chronic pancreatitis can be made. However, it is well known that 18-30% of patients with CFTR related disorders (congenital bilateral absence of the vas deferens and bronchiectasis) have only one CFTR mutated allele. [1] [2] [3] Thus despite our study being based on only the two most common CFTR mutations (F508del and 5T), these two alterations should suYce to rule out or confirm a potential role of CFTR in patients with chronic pancreatic diseases. Furthermore, complete analysis of CFTR in the general population has led to the identification of amino acid variants of yet unknown functional significance in about 10% of subjects. 4 It is highly likely that complete analysis of CFTR would render a large number of amino acid changes of uncertain clinical and functional consequences, as it has been shown for patients with asthma. 5 As we proposed in our paper (Gut 2001;48:70-4), only the design of large studies specifically addressing these issues in target and adequate control populations and a comprehensive molecular analysis of CFTR will answer the question on the role of this gene in chronic pancreatic disease. 
Reply
X ESTIVILL T CASALS
Alcohol, obesity, and TNF-
EDITOR,-The conclusions reached by Wigg et al (Gut 2001; 48:206-11) about the origin and importance of tumour necrosis factor (TNF-) in non-alcoholic steatohepatitis (NASH) patients have failed to take into account the relationship between even modest alcohol consumption and TNF-production and function. The authors found a lack of correlation between obesity and TNFlevels in NASH patients and concluded that TNF-, which they see as central to the pathogenesis of the condition, must have other sources.
We first described the strong correlation between obesity and serum TNF-in 1998. 1 Adipose tissue synthesises a number of proinflammatory cytokines. 2 The negative correlation found in the Adelaide study is surprising given the findings in larger studies of non-NASH subjects and may be due to the small study numbers and not correcting for modest alcohol intake.
Alcohol consumption is considered a risk factor for the development and progression of liver disease in patients with fatty livers. We previously showed a strong negative correlation between any alcohol consumption and serum TNF-levels in a general population sample. Modest alcohol consumption is known to suppress TNF-production by monocytes, probably by suppressing posttranscriptional TNF-production. 3 Furthermore, alcohol also has eVects on TNFfunction mediated via high density lipoprotein (HDL). Alcohol enhances HDL levels by stimulating lipoprotein lipase activity in adipose tissue. 4 HDL not only inhibits TNF-release from macrophages 5 but also protects certain cells against TNF-induced damage. 6 If TNF-is important, then modest alcohol intake should be protective via suppression of TNF-. This raises the possibility that TNF-is not important in early steatohepatitis.
In defining patients with NASH, alcohol consumption must be rigorously excluded. In the Adelaide study, 10 of 22 patients drank up to 20 g of alcohol per day; however, even modest amounts of alcohol have eVects on TNF-levels and function.
The known interaction between alcohol and obesity in the pathogenesis of fatty liver and steatohepatitis suggests that investigators must look to factors other than TNF-in studying the early pathogenesis of this condition. In the same way that altered cytokine homeostasis has been implicated in alcoholic liver disease, NASH is probably caused by changes to more than one proinflammatory cytokine. Interleukin 6 (IL-6) is a proinflammatory cytokine, a hepatocyte stimulating factor, and inhibitor of hepatic apoptosis. It has been suggested that hepatic steatosis is due to the rate of hepatocyte apoptosis becoming insuYcient to match the rate of hepatocyte proliferation.
7 IL-6 induced liver regeneration may render the liver more susceptible to the eVects of other insults. Unlike TNF-, serum IL-6 exhibits a positive correlation with both obesity and alcohol intake (fig 1) . 1 8 So far IL-6 has not been studied in the aetiology of NASH.
Future studies examining the link between TNF-and NASH will need to rigorously control for alcohol consumption and assess many other aspects of the inflammatory cytokine network. Reply EDITOR,-Our recent paper found increased small bowel bacterial overgrowth (50% versus 22%) and twofold increased systemic levels of tumour necrosis factor (TNF-) in patients with non-alcoholic steatohepatitis (NASH) compared with control age and sex matched subjects (Gut 2001;48:206-11). Poullis and Mendall question the finding of elevated TNF-levels in blood in NASH subjects and quote their own work of elevated TNF-levels in obese, male, middle aged subjects. 1 There was no correlation between TNF-levels and obesity in our study whereas their study showed a correlation with obesity. How can this be explained? The question comes down to whether TNF-is being produced predominantly in adipose tissue or in the liver, and which of these contributes to elevated systemic levels. At the moment this cannot be resolved. TNF-will need to be investigated in liver biopsies and TNF-levels sampled from the hepatic vein (not entirely impossible). The same should be done in animal models of obesity. In the meantime, it would be important to ascertain what proportion of obese patients have unrecognised NASH and whether this could explain the elevated TNF-levels in obesity. Several lines of evidence suggest TNF-is upregulated in the liver in alcoholic liver disease and presumably this is reflected by raised serum levels. We doubt therefore whether a low (<20 g/day) consumption of alcohol reduces systemic TNF-levels but this could be formally studied. We have re-examined our data and found that there is no diVerence in mean TNF-levels between those who reported no alcohol consumption and those who drank alcohol. Finally, we would also comment from our recent work that shows that the C 14 -D-xylose/H 2 -CH 4 breath test is only positive in 60-69% of cases of small bowel bacterial overgrowth, 2 mostly because it depends on bacterial overgrowth being present on the day of testing. Thus small bowel overgrowth may have contributed even more to NASH than indicated in our paper. Dyspepsia is like pornography-everyone thinks they know what it is but no one can agree on a definition. This is where the analogy ends, however, as there are plenty of books on pornography but few have been written on dyspepsia compared with other areas of gastroenterology. Out of idle curiosity I searched the Internet for books on irritable bowel syndrome and found 25 published in the past five years compared with only three titles specifically on dyspepsia. This is surprising given that dyspepsia represents 50% of a gastroenterologist's workload and it is refreshing to see an up to date book on the subject. The book discusses the epidemiology, pathophysiology, diagnosis, and treatment of dyspepsia in a methodical fashion. There are contributions from an illustrious list of authors many of whom have international reputations in the field of dyspepsia research. Each chapter acts as a well informed review on a particular aspect of dyspepsia. The editors and contributors are to be congratulated on ensuring each piece is authoritative yet relatively short and accessible. This approach means that the reader can dip into a chapter most relevant to them and receive up to date information on that topic.
If you read the book from cover to cover however the introductions to each chapter become somewhat repetitive. I became a little tired of hearing about the clinical importance of dyspepsia. There is a chapter on the definition of dyspepsia and yet five other chapters also define the condition. This can be confusing as some characterise dyspepsia as any symptom referable to the upper gastrointestinal tract whereas others take the more restrictive Rome II definition. The editors have taken a very broad definition of dyspepsia and have included chapters on gastro-oesophageal reflux disease. This will probably irritate some experts who believe reflux disease should be excluded. However, there is no diagnostic test for dyspepsia and therefore attempts at defining it become reminiscent of theological arguments about how many angels will fit on the point of a needle.
Another minor quibble is that there were only two chapters explicitly discussing Helicobacter pylori and dyspepsia. I realise that H pylori is only one of many causes of dyspepsia but given that this is one of the major discoveries in medicine over the past 20 years, more information on the organism might have been appropriate.
A more major criticism is that the book does not have a chapter that specifically discusses the management of dyspepsia. This is touched on in a few chapters but there are no firm conclusions reached and recent important trials in this area are not fully discussed. This book may therefore disappoint clinicians wanting a more didactic text on the evidence for the management of dyspepsia.
I would warmly recommend this book to all gastroenterologists with an interest in dyspepsia. This is a rapidly changing field which hopefully will be reflected in new editions of this work. Nausea is an extraordinarily common and under appreciated symptom that aZicts patients and non-patients alike. In a North American population, approximately 15% of subjects surveyed had moderate to severe nausea in the past month. Thankfully, the nausea most of us experience is brief and self limited. Almost all of the medical and surgical subspecialties however have patients who are intermittently and chronically nauseated. Unfortunately, little progress has been made in the study of nausea from a pathophysiological and treatment viewpoint.
The authors of the book seek to change this situation and have produced a most interesting and readable book about nausea and vomiting for students, primary care physicians, and researchers interested in these unique human symptoms. Gastroenterologists with a clinical or research interest in nausea and vomiting will also find this book helpful in that it brings together a large amount of information that is not easily accessible to us.
The book is basically divided into three parts: in the first 14 chapters the relevant anatomy and physiology of nausea and vomiting, various research methodologies, therapeutics, relevant neuropeptides, and the economic impact of nausea and vomiting are covered. Next there are 18 chapters outlining "hands on" advice for diagnosing and treating the patient with nausea and vomiting. Finally, the last chapter in an excellent and extensive essay on nausea/vomiting as an evolutionary response of the ancient reptilian brain: the reptilian brain appears to be responding to an increasing number of nauseogenic precipitants created by our modern lifestyles, technologies, and therapeutics, as well as specific diseases/ disorders. Why is this?
The authors raise many provocative issues. They reject the simplistic notion that nausea and vomiting are regularly activated as a response to a putative ingestion of toxic substances. This time honoured concept simply does not reflect the many situations where nausea and vomiting occur in the absence of toxic ingestants. Olfactory system stimuli are discussed in detail with regards to nausea and vomiting during pregnancy. The authors review an interesting concept that relates nausea and vomiting and gravity, as gravitational forces aVect the basic organisation of brain function. Refreshing ideas and perspectives on nausea and vomiting are oVered that encompass philosophy and psychology viewpoints, as well as physiology and pharmacology.
Nausea is more debilitating than vomiting. The authors argue that nausea should be clearly separated from vomiting in terms of studying pathophysiological mechanisms and developing therapies. Indeed, vomiting is the cure for nausea (at least temporarily)! Nausea is an "early warning system" evoked as the organism attempts to maintain homeostasis in response to the nauseogenic stimuli. Vomiting is described as an "accident" of cascading stimuli that ultimately overwhelm homeostasis and the inhibitory circuits that prevent the uncontrollable and potentially injurious vomiting reflex.
Gastroenterologists are not the only medical providers dealing with the problems of nausea and vomiting. "Nausea is in the air; nausea is everywhere" is a phase I often use when lecturing about the multidisciplinary problem of nausea and vomiting. The second major portion of the book incorporates 18 chapters in which a practical approach to the diagnosis and treatment of nausea and vomiting is described for many medical and surgical specialties. From allergy and immunology to gastroenterology, oncology, surgery, and sports and space medicine these chapters are an introduction to the treatment of nausea and vomiting by various specialists.
These chapters are a bit uneven in their thoroughness and somewhat redundant in that each specialty ultimately uses similar drugs and comfort techniques for their patients. The tremendous lack of progress in the therapy for nausea and vomiting makes this area an open field for drug and non-drug development.
The final chapter is an extensive essay on nausea and vomiting that encompasses stimulating paragraphs that are well worth reading for any student of nausea and vomiting symptoms. Topics range from the adaptive purpose of nausea as a warning sign of ongoing problems in the internal/external environment, as marshalling social support for the suVerer, and as a powerful stimulus for problem solving to avoid these symptoms in the future.
I highly recommend this book as thoughtful and thought provoking reading for anyone interested in the common and sometimes debilitating symptoms of nausea and vomiting. The authors provide excellent reviews and new insights that are now necessary to consider in the fight against nausea and vomiting. Would I feel tempted to buy this book? At £12.00 it is a give away price and an excellent buy. It provides an up to date and easily read guide to our present understanding of the cause, diagnosis, and management of Crohn's disease and ulcerative colitis. It certainly provides an authoritative handbook for specialist registrars or even concerned patients. Its one weakness lies in the absence of referencesbut within 100 pages could one realistically expect to achieve this? Its role as a handbook for a consultant is less clear. Most of the information it contains should be already known to him or her, but it certainly could refresh that knowledge.
Inflammatory bowel disease is laid out in an attractive format with clear subtitles, useful summary tables, and a good range of illustrations. The impact of inflammatory bowel disease on aspects of life such as fertility, sexual relations, education, employment, and the consequences of the disease in childhood are dealt with in a limited way. The growing role of the specialist nurse in counselling and support is not considered in the book although it could provide useful background reading for anyone working in such a role.
I was particularly impressed by the inclusion of such esoteric treatments as arsenic suppositories in the text although this was omitted from the index. Remicaide was also absent from the index but dealt with in the text. In future editions the index could be strengthened by a more uniform inclusion of key terms. Another useful innovation could be the listing of reliable web sites.
With the growth of expensive, lengthy, but definitive textbooks that are almost by definition out of date at the time of publication, there is a clear need for cheap authoritative works that will have a relatively short shelf life and can be quickly revised or replaced. The philosophy behind the Health Press gives hope that they may be able to fill this important niche in the medical book market. Critical to this approach is the need for low cost. We are in the throes of a revolution in the printing world, the ramifications of which cannot be accurately foreseen but are certainly as likely to have as dramatic eVect on global culture as did Johann Gutenberg's invention of printing in the 15th century. Maybe we should all be pleased that we are living right in the middle of the revolution in communications technology. It is an endless source of fascination to listen to those who just a few years ago could not distinguish a RAM from a ROM, now feeling free to wax lyrical to all within earshot about the latest bit of "state of the art" technology that they own. How good it is to be at the cutting edge of information technology.
Yet, maybe not everyone is head over heels in love with IT. While the medical and particularly the academic community are keen to grasp all the opportunities, there must be many publishers who are rather fearful about what the future might bring. For them, like for almost all of us, change brings uncertainty. But it is not good to question technological progress in the UK just now. We have a modernising government and its leader is fond of saying that he is proud of his country's past, but he does not want to live in it! So what will modernisation bring to the publishing world. A whole generation is now being brought up to look upon the personal computer as the main means of communication. Conventional correspondence is now sneeringly dismissed as "snail mail". Maybe daily newspapers will hang in there a bit longer but what is the future of medical journals?
All of these thoughts were going through my mind as I read this book, the first edition of which was published six years ago. The sheer range of what can now be done interventionally through an endoscope is quite breathtaking. There is a series of essays on therapeutic endoscopy nearly all of which are of very high quality indeed. The publisher, WB Saunders, has served the editors very well. I think this book has been most beautifully produced-the illustrations are generally very fine and the reproduction of colour photographs is quite superb. This is a book that should be read by every trainee.
Yet there is a problem. It is something of a truism that medical textbooks are out of date before they are published. Of course that is always true, even in an area such as this where the pace of technological progress out speeds the publishing schedule. However, the problem here is rather deeper. In many ways, this book is a manual. It is full of helpful tips on "how to do it" and it is very good on pitfalls and how to avoid them. The problem is that the medium of a textbook just cannot be the way of the future for this sort of book. As most of the neologisms in the IT language, multimedia is a fairly ghastly word, nevertheless one just feels there ought to be a CD or DVD to go with the book.
Whether anybody will be publishing books like this in five years time is anyone's guessbut I wouldn't bet on it. Doubtless trees will be happier but in any case the present publishers state proudly in a preface that their policy is "to use paper manufactured from sustainable forests". Jolly good of them too! figure 2 . The correct figure is printed here. The one line of text that describes the figure, under the heading "intrahepatic cholangiocarcinoma" on p817, should now read, "There was, on average, a 12-fold increase in ASpMR per 100 000 population in ages 45 and above, with larger increases at older ages and in women (fig 2A, B) ". The authors apologise for this error, and wish to point out that all the rest of the data are correct, and this does not change the findings reported upon in the paper or the interpretation.
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Figure 2 Age specific mortality rates per 100 000 population in England and Wales in (A) females and (B) males for intrahepatic cholangiocarcinoma.
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